--- title: "TB-500 | PepTracker Pro" description: "A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "TB-500", "description": "A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.", "url": "https://peptrackerpro.com/peptides/tb-500", "lastReviewed": "2026-05-11", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "TB-500", "item": "https://peptrackerpro.com/peptides/tb-500" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Athletes researching recovery peptides?", "acceptedAnswer": { "@type": "Answer", "text": "TB-500 is a research peptide studied in preclinical models. A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery." } }, { "@type": "Question", "name": "People interested in wound healing research?", "acceptedAnswer": { "@type": "Answer", "text": "TB-500 is a research peptide studied in preclinical models. A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery." } }, { "@type": "Question", "name": "Those exploring anti-inflammatory compounds?", "acceptedAnswer": { "@type": "Answer", "text": "TB-500 is a research peptide studied in preclinical models. A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ TB-500 **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # TB-500 Medium Evidence A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery. Aliases Thymosin Beta-4 +1 more Evidence Medium Evidence Last Updated 2026-05-11 Reading Time 2 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Why Researchers Study It](#why-researchers-study) 4. [Proposed Mechanisms](#proposed-mechanisms) 5. [Evidence Snapshot](#evidence-snapshot) 6. [Commonly Discussed Benefits](#benefits) 7. [Safety & Cautions](#safety) 8. [Comparisons](#comparisons) 9. [Calculator Tools](#calculator) 10. [Citations](#citations) ## What It Is TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a 43-amino acid peptide naturally produced by the thymus gland. It plays a role in cell migration, blood vessel formation, and tissue repair. Research has explored its potential in wound healing, cardiac repair, and reducing inflammation. In 2026, new human trial data emerged from a study enrolling patients recovering from acute myocardial infarction (AMI), randomized to receive Thymosin Beta-4 or placebo as adjunct therapy after standard revascularization. The trial showed measurable improvements in cardiac recovery metrics. The injectable formulation RGN-352, containing synthetic Tβ4, has progressed toward Phase 2 clinical trials for acute myocardial infarction based on these and earlier preclinical findings. Mechanistically, TB-500 upregulates VEGF expression in cardiac tissue, modulates the inflammatory cascade to preserve clearance while blunting prolonged inflammation that contributes to adverse cardiac remodeling, and activates epicardial progenitor cells. The FDA Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to discuss TB-500 and other peptides for potential addition to the 503A Bulks List. Public comments can be submitted via docket FDA-2025-N-6895, open until July 22, 2026. Also known as: Thymosin Beta-4, Tβ4 ## Regulatory Status Category 1 — Bulk Compounding (PCAC review July 23, 2026) Moved from Category 2 back to Category 1 per HHS announcement February 27, 2026. FDA PCAC will review TB-500 (free base and acetate) on July 23, 2026 for potential 503A Bulks List inclusion for wound healing. Public comment docket FDA-2025-N-6895 open until July 22, 2026. Effective: February 2026 [View FDA Source](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) ## Why Researchers Study It TB-500 is studied for its role in cell migration and tissue remodeling. As a synthetic form of Thymosin Beta-4, it is one of the most abundant intracellular proteins, suggesting fundamental biological significance in wound repair and cardiovascular regeneration research. ## Proposed Mechanisms - Sequesters G-actin monomers, promoting cell motility and migration - Stimulates angiogenesis and new blood vessel formation - Reduces pro-inflammatory cytokines at injury sites - Promotes keratinocyte and endothelial cell migration for wound closure - May support cardiac progenitor cell activation post-injury ## Evidence Snapshot Medium Evidence Low Medium High Study Type Model Outcome Link Animal (mouse) Dermal wound model Accelerated wound closure and reduced scarring [Source](https://pubmed.ncbi.nlm.nih.gov/) Animal (rat) Myocardial infarction Improved cardiac function and reduced infarct size [Source](https://pubmed.ncbi.nlm.nih.gov/) In vitro Endothelial cell migration assay Significant increase in cell migration rate [Source](https://pubmed.ncbi.nlm.nih.gov/) Human (2026) Acute myocardial infarction — adjunct to standard revascularization Measurable improvements in cardiac recovery; VEGF upregulation and epicardial progenitor cell activation observed [Source](https://peptiq.io/blog/tb500-cardiac-recovery-human-trials-2026) ## Commonly Discussed Benefits [Recovery](/benefits/recovery)[Wound Healing](/benefits/wound-healing)[Inflammation](/benefits/inflammation)[Muscle Growth](/benefits/muscle-growth)[Joint Health](/benefits/joint-health) Researching TB-500 ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=tb-500) ## Safety & Cautions - Primarily studied in animal models, though 2026 human cardiac trial data has emerged - Human clinical data is still limited - Not FDA-approved - Potential interactions not fully characterized - RGN-352 formulation advancing toward Phase 2 for cardiac indications ## Comparisons See how TB-500 compares to related peptides: [TB-500 vs BPC-157](/compare/tb-500-vs-bpc-157) [TB-500 vs GHK-Cu](/compare/tb-500-vs-ghk-cu) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Goldstein AL. et al. — Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012 [PubMed](https://pubmed.ncbi.nlm.nih.gov/) 2. \[2\] Crockford D. — Development of thymosin beta4 for wound healing. Ann N Y Acad Sci. 2007 [PubMed](https://pubmed.ncbi.nlm.nih.gov/) 3. \[3\] TB-500 and Cardiac Recovery: What the 2026 Human Trial Data Shows — PeptIQ 2026 [PubMed](https://peptiq.io/blog/tb500-cardiac-recovery-human-trials-2026) 4. \[4\] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee [PubMed](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) ### Keep researching in the app - Log TB-500 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=tb-500) [Browse more peptides](/peptides) ## Related Peptides ### BPC-157 Medium Evidence A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties. [Recovery](/benefits/recovery)[Gut Health](/benefits/gut-health)[Wound Healing](/benefits/wound-healing)[Joint Health](/benefits/joint-health)+2 more [View Details](/peptides/bpc-157) [\+ Compare](/compare?select=bpc-157)[](https://app.peptrackerpro.com/?add=bpc-157) ### GHK-Cu High Evidence A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects. [Skin](/benefits/skin)[Anti-Aging](/benefits/anti-aging)[Wound Healing](/benefits/wound-healing)[Hair Growth](/benefits/hair-growth)+2 more [View Details](/peptides/ghk-cu) [\+ Compare](/compare?select=ghk-cu)[](https://app.peptrackerpro.com/?add=ghk-cu) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.